Roivant Sciences jumps on positive Phase 2 lung-disease data
+18.75% to $41.48 from $34.93
What moved ROIV
- Roivant said Pulmovant’s inhaled drug mosliciguat showed a clinically meaningful, statistically significant improvement in the Phase 2 PHocus study in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Data presented at the European Respiratory Society Congress covered pulmonary vascular resistance, six-minute walk distance and NT-proBNP measures.
- Roivant said it is advancing mosliciguat into an already-underway Phase 3 study, PHrontier.
- Shares rallied about 24% on the results.
Sources: Endpoints News · GlobeNewswire (Roivant release) · TheStreet